Ischemix, LLC
Ischemix, Inc. is a privately-held pharmaceutical company dedicated to developing novel, proprietary cytoprotective compounds for the treatment of serious diseases and conditions, including traumatic brain injury (TBI). The company's mission is to advance cytoprotective therapies that can prevent and treat serious health issues, leveraging innovative compounds like CMX-2043. With a focus on safety, efficacy, and patent protection, Ischemix aims to bring effective treatments to market that address unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Products
Lead small-molecule cytoprotective injectable (clinical candidate)
A small-molecule, injectable cytoprotective candidate derived from alpha-lipoic-acid analogs, engineered for multi-modal activity across tissue types and developed for traumatic brain injury and other ischemic injuries.
Lead small-molecule cytoprotective injectable (clinical candidate)
A small-molecule, injectable cytoprotective candidate derived from alpha-lipoic-acid analogs, engineered for multi-modal activity across tissue types and developed for traumatic brain injury and other ischemic injuries.
Services
Preclinical-to-Phase-2 small-molecule development
End-to-end development services covering medicinal chemistry, preclinical efficacy and safety studies, regulatory-enabling studies and Phase 1 clinical execution in partnership with CROs.
Preclinical-to-Phase-2 small-molecule development
End-to-end development services covering medicinal chemistry, preclinical efficacy and safety studies, regulatory-enabling studies and Phase 1 clinical execution in partnership with CROs.
Expertise Areas
- Cytoprotective small-molecule drug development
- Preclinical efficacy and translational neuroscience (TBI models)
- Clinical trial design and execution (SAD/MAD and randomized Phase 2)
- Preclinical pharmacology and toxicology
Key Technologies
- Alpha-lipoic-acid analog medicinal chemistry
- Rodent and porcine traumatic brain injury models
- Actigraphy-based behavioral monitoring
- Magnetic resonance imaging (MRI) analysis